WOBURN, Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera's SQore platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass.

Yuhong Zeng, Ph.D., Director of Formulation at Comera, will present data from Comera's SQore platform which is designed to transform intravenous biologics such as monoclonal antibodies (mAbs) into subcutaneous (SQ) formulations. Comera's SQore platform has been successfully tested with over 40 mAbs, with viscosity reductions of up to 85%. Comera uses the SQore platform to identify the driving forces for high viscosity and select excipients that inhibit attractive protein-protein interactions to lower viscosity.

Robert Mahoney, Ph.D., Chief Scientific Officer at Comera, commented, "The challenge many have faced with SQ delivery is that high-concentration antibody solutions can become viscous, and prone to physical instability, such as aggregation, precipitation, or denaturation. We have been able to successfully reduce the viscosity of a diverse range of monoclonal antibodies, demonstrating the versatility and remarkable capabilities of our SQore platform."

Comera is also presenting data from a preclinical study, previously published in the Journal of Pharmaceutical Sciences, that found that a caffeine excipient reduced viscosity of the monoclonal antibody ipilimumab without any adverse impact on antibody pharmacokinetic properties. The addition of one or more excipients, such as caffeine, selectively interrupts intermolecular interactions to reduce viscosity of high concentration mAb formulations.

Dr. Mahoney continued, "The data reinforces the strength of our SQore platform in reformulating high-viscosity monoclonal antibody solutions and underscores the potential of caffeine and other core excipients as viscosity-reducing agents for subcutaneous monoclonal antibody formulations. Ultimately, the mission driving our research is to enhance convenience, decrease costs and increase compliance by reformulating therapies for patient-delivered SQ injections."

The presentation, titled "SQore Enabled High Concentration mAb Formulations for Patient-Delivered Subcutaneous Delivery," can be accessed following the event  

About Comera Life Sciences

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.